Talzenna

Chemical Nametalazoparib
Dosage FormCapsule (oral; 0.25 mg, 0.5 mg, 1 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanyPfizer Inc.
Approval Year2018

Indication

  • To treat deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.
Last updated on 12/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Talzenna (Talazoparib) Prescribing Information 2018Pfizer Inc., New York, NY
Document TitleYearSource
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.2018The New England Journal of Medicine